A specialty pharmaceutical company - with the aim of becoming a leader in the treatment of addiction

Q4 and FY19 - Strong fundamentals in place to fuel strategy for future growth

JANUARY 30, 2020 – In 2019 we delivered the strongest financial results, with Q4 being no exception. The development was driven YoY increased net revenues for Zubsolv and strong cost control. Operationally, we signed two partnership agreements with GAIA to develop digital therapeutics for the treatment of Opioid and Alcohol Use Disorder and we made pipeline progresses. With a solid cash position we will continue to deliver our strategy for future growth with the aim to build an even more exciting future.

Presentation of the Q4 report

JANUARY 30, 2020 – Listen to Nikolaj Sørensen CEO and Joe DeFeo CFO presenting the latest development in Q4 and the way going forward. After the presentation there is a Q and A session.

Promising results for OX338

JANUARY 29, 2020 - The PK study for OX338, evaluating novel formulations of ketorolac for the treatment of pain showed promising results. The formulations demonstrated improved bioavailability and tolerability compared to the commercially available reference product. The next step is to further optimise the formulation to ensure obtaining a unique product profile and strong IP protection.

Save the Date – Capital Markets Day focusing on Digital Therapeutics

Investors, analysts and media are invited to attend our Capital Markets Day that will take place at, Helio GT 30, Grev Turegatan 30, Stockholm, Sweden. The program will start at 1:30 pm CET, with registration from 1:00 pm CET. The event plans to end at 4.00 pm CET. A formal invitation with a complete program will be sent out at a later date. #strategy #pipeline #digitalhealth